Monitoring AML1-ETO and CBFβ-MYH11 transcripts in acute myeloid leukemia

Current Oncology Reports

Volumn 5, Issue 5, 2003, Pages 399-404

  Liu Yin, John A ^a   Frost, Lindsay ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; CORE BINDING FACTOR; CORE BINDING FACTOR BETA; DNA POLYMERASE; DOUBLE STRANDED DNA; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 11; PROTEIN ETO; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; CBFBETA MYH11 FUSION PROTEIN; CBFBETA-MYH11 FUSION PROTEIN; ONCOPROTEIN; RNA; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHROMOSOME 16; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CLINICAL STUDY; CYTOGENETICS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GENE AMPLIFICATION; GENE FUSION; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HUMAN; KARYOTYPING; LEUKEMIA REMISSION; LYMPHOCYTE TRANSFUSION; METHODOLOGY; MINIMAL RESIDUAL DISEASE; NONHUMAN; PATIENT MONITORING; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; ACUTE DISEASE; ARTICLE; GENETICS; METABOLISM; MONITORING; MYELOID LEUKEMIA; POLYMERASE CHAIN REACTION;

ACUTE DISEASE; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HUMANS; LEUKEMIA, MYELOID; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, NEOPLASM; TRANSCRIPTION FACTORS;

EID: 3142511057     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0026-6     Document Type: Review

References (48)

1. Van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al.: Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood: a prospective study of the International BFM Study group. Lancet 1998, 352:1731-1738.
2. Olavarria E, Kanfer E, Szydlo R, et al.: Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565.
3. Liu Yin JA, Grimwade D: Minimal residual disease evaluation in acute myeloid leukemia. Lancet 2002, 360:160-162.
4. Grimwade D, Walker H, Oliver F, et al.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. Blood 1998, 92:2322-2333.
5. Liu Yin JA: Minimal residual disease in acute myeloid leukemia. Baillieres Best Pract Res Clin Haematol 2002, 15:119-135.
6. Tobal K, Liu Yin JA: Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML 1-MTG8 transcripts in AML-M2 with t(8;21). Blood 1996, 88:3704-3707.
7. Cross NCP: Quantitative PCR techniques and applications. Br J Haematol 1995, 89:693-697.
8. Evans PAS, Short MA, Jack AS, et al.: Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML. Leukemia 1997, 11:365-369.
9. Higuchi R, Dollinger G, Walsh P: Simultaneous amplification and detection of specific DNA sequences. Biotechnology 1992, 10:413-417.
10. Holland P, Abramson R: Detection of specific polymerase chain reaction product by utilising the 5′ to 3′-exonuclease activity of Thermus Aquaticus DNA polymerase. Proc Natl Acad Sci U S A 1991, 88:7276-7280.
11. Erickson P, Gao J, Change KS, et al.: Identification of breakpoints in t(8;21) AML and isolation of a fusion transcript with similarity to Drosophilia segmentation gene runt. Blood 1992, 80:1825-1831.
12. Downing JR, Head DR, Curcio-Brint AM, et al.: An AML 1-ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia combining the (8;21) (q22;q22) translocation. Blood 1993, 81:2860-2865.
13. Nucifora G, Birn DJ, Erickson R et al.: Detection of DNA rearrangements in the AML 1 and ETO loci and of an AML 1/ETO fusion in RNA in patients with t(8;21) acute rayeloid leukemia. Blood 1993, 81:883-888.
14. Swirsky DM, Li YS, Matthews JG, et al.: (8;21) translocation in acute granulocytic leukemia: cytological, cytochemical and clinical features. Br J Haematol 1994, 56:199-213.
15. Nucifora G, Larson RA, Rowley JD: Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood, 1993, 82:712-715.
16. Kusec R, Laczika K, Knobl et al.: AML 1/ETO fusion MRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994, 8:735-739.
17. Saunders MJ, Tobal K, Liu Yin JA: Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukemia type M2 after chemotherapy or bone marrow transplantation. Leukemia Res 1994, 18:891-895.
18. Jurlander J, Caligiuri MA, Ruutu T, et al.: Persistence of the AML 1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996, 88:2183-2191.
19. Miyamoto T, Weissman IL, Akashi K: AML 1/ETO-expressing non-leukaemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A 2000, 97:7521-7526.
20. Rhoades KL, Hetherington CJ, Harakawa N, et al.: Analysis of the role of AML 1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 2000, 96:2108-2115.
21. Yuan Y, Zhou L, Miyamoto et al.: AML 1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A 2001, 98:10398-10403.
22. Basecke J, Cepek L, Mannhalter C, et al.: Transcription of AML 1/ETO in bone marrow and cord blood of individuals without acute myelogenous leukemia. Blood 2002, 100:2267-2268.
23. Kwong YL, Chan V, Wong FK, et al.: Use of polymerase chain reaction in the detection of AML 1/ETO fusion transcript in t(8;21). Cancer 1995, 75:821-825.
24. Satake N, Maseki N, Kozu T et al.: Disappearance of AML 1-MTG8 (ETO) fusion transcript in acute myeloid leukemia patients with t(8;21) in long-term remission. Br J Haematol 1995, 91:892-898.
25. Morschhauser F, Cayuela JM, Martini S, et al.: Evaluation of minimal residual disease using reverse transcriptase polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicentre study of 51 patients. J Clin Oncol 2000, 18:788-794.
26. Tobal K, Newton J, Macheta M, et al.: Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000, 95:815-819.
27. Wattjes MP, Krauter J, Nigel S, et al.: Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantitation of AML1-MTG8 fusion transcripts in t(8;21) positive AML. Leukemia 2000, 14:329-335.
28. Krauter J, Wattjes MP, Nigel S et al.: Real-time RT-PCR for the detection and quantitation of AML 1-MTG8 fusion transcripts in t(8;21) positive AML patients. Br J Haematol 1999, 107:80-85.
29. Sugimoto T, Das H, Imoto et al.: Quantitation of minimal residual disease in t(8;21) positive acute myelogenous leukemia patients using real-time quantitative RT-PCR. Am J Haematol 2000, 64:101-106.
30. Le Beau MM, Larson RA, Bitter MA, et al.: Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia: a unique cytogenetic-clinico-pathological association. N Engl J Medicine 1983, 309:630-636.
31. Liu P, Tarle SA, Hajra A, et al.: Fusion between transcription factor CBFbeta/PEBP 2beta and a myosin heavy chain in acute myeloid leukemia. Science 1993, 261:1041-1044.
32. Claxton DF, Liu P, Hsu HB, et al.: Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 1994, 83:1750-1756.
33. Liu P, Hajra A, Wijmenga C, Collins FS: Molecular pathogenesis of the chromosome 16 inversion in the M4 Eo subtype of acute myeloid leukemia. Blood 1995, 85:2289-2302.
34. Langabeer SE, Walker H, Gale RE, et al.: Frequency of CBFbeta/MYH11 fusion transcripts in patients entered into the UK MRC AML trials. Br J Haematol 1997, 96:736-739.
35. Hebert J, Cayuela JM, Daniel MT, et al.: Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Blood 94, 84:2291-2296.
36. Tobal K, Johnson PRE, Saunders MJ, et al.: Detection of CBFbeta/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol 1995, 91:104-108.
37. Poirel JM, Radford-Weiss I, Rack K, et al.: Detection of the chromosome 16 CBFbeta-MYH11 fusion transcript in myelomonocytic leukemias. Blood 1995, 85:1313-1322.
38. Elmaagacli AH, Beelen DW, Kroll M, et al.: Detection of CBFbeta/MYH11 fusion transcript in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998, 21:159-166.
39. Costello R, Sainty D, Blaise D et al.: Prognostic value of residual disease monitoring by polymerase chain reaction in patients with CBFbeta-MYH11 positive acute myeloblastic leukemia. Blood 1997, 89:2222-2223.
40. Marcucci G, Caligiuri MA, Bloomfield CD: Defining the 'absence'of the CBFb-MYH11 fusion transcripts in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. Blood 1997, 90:5022-5024.
41. Laczika K, Novak M, Hilgarth, et al.: Competitive CBFbeta-MYH11 reverse transcription polymerase chain reaction for quantitative assessment of minimal residual disease during post-remission therapy in acute myeloid leukemia with inversion (16): a pilot study. J Clin Oncol 1998, 16:1519-1525.
42. Marcucci G, Caligiuri MA, Dohner H, et al.: Quantification of CBFbeta/MYH11 fusion transcripts by real-time RT-PCR in patients with inv(16) acute myeloid leukemia. Leukemia 2001, 15:1072-1080.
43. Buonamici S, Ottaviani E, Testoni N, et al.: Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a durable state. Blood 2002, 99:443-449.
44. Guerrasio A, Pilatrino C, De Micheli D, et al.: Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemia by qualitative and quantitative RT-PCR amplification of fusion transcripts. Leukemia 2002, 16:1176-1181.
45. Langabeer SE, Walker H, Rogers JR, et al.: Incidence of AML 1/ETO fusion transcripts in patients entered into the MRC AML trials. Br J Haematol 1997, 99:925-928.
46. Mrozek K, Prior TW, Edwards C, et al.: Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2001, 19:2482-2492.
47. Burnett AK, Goldstone AH, Stevens RMF, et al.: Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML-10 trial. Lancet 1998, 351:700-708.
48. Burnett AK, Wheatley K, Goldstone AH, et al.: The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002, 188:385-400.